Variable | FRA positive | FRA negative | Total | P valuea |
---|---|---|---|---|
N (%) | N (%) | |||
Marker | ||||
ER/PR(+) | 4 (14%) | 24 (86%) | 28 | |
ER/PR(-) | 14 (45%) | 17 (55%) | 31 | 0.012 |
Her2(+) | 2 (15%) | 11 (85%) | 13 | |
Her2(-) | 16 (35%) | 30 (65%) | 46 | 0.307 |
ER/PR/Her2(-) | 12 (67%) | 6 (33%) | 18 | <0.0001 |
[ER/PR(+) or Her2(+) vs ER/PR/Her2(-)] | ||||
TNM Classification | ||||
T1 | 3 (43%) | 4 (57%) | 7 | |
T2 | 10 (26%) | 29 (74%) | 39 | |
T3 | 5 (63%) | 3 (37%) | 8 | |
T4 | 0 (0%) | 5 (100%) | 5 | |
Nodal Status | ||||
N0 | 18 (35%) | 33 (65%) | 51 | |
N1/N2b | 0 (0%) | 8 (100%) | 8 | 0.092 |
Tumor Grade | ||||
Grade 1 | 1 (14%) | 6 (86%) | 7 | |
Grade 2 | 12 (36%) | 21 (64%) | 33 | 0.393 |
Grade 3 | 5 (26%) | 14 (74%) | 19 | 0.6465c |